RSS Xconomy

  • Evofem’s David Friend Appointed Daré Bio Chief Scientific Officer June 22, 2018
    David Friend has been appointed chief scientific officer of San Diego-based Daré Biosciences (NASDAQ: DARE). Friend comes to Daré from another San Diego biotech company, Evofem Biosciences (NASDAQ: EVFM), where he was chief scientific officer. Daré develops treatments focusing on women’s reproductive health. The company gained its public stock listing last year through a reverse […]
  • Gemini Therapeutics Names Sandra Rojas-Caro Chief Medical Officer June 22, 2018
    Sandra Rojas-Caro has been appointed chief medical officer of Cambridge, MA-based Gemini Therapeutics. She was most recently chief medical officer for Aeglea BioTherapeutics. In other moves, Gemini named Claude Knopf to the position of chief business officer and promoted Scott Lauder to chief technology officer. Last fall, Gemini raised $42 million in Series A financing […]
  • Bio Roundup: Duchenne Data, Roche Buys Foundation, IPO Wave & More June 22, 2018
    Biotech financing is a cyclical thing. Two years ago, the IPO window was unlatched but a number of companies ended up withdrawing their stock offerings. Others that pushed their IPOs through couldn’t sell shares at the price they wanted. This year, the IPO window is wide open. A total of 93 IPOs have priced as […]
  • Bio IPO Madness: Six Biotech Startups Raise $568M in 24 Hours June 21, 2018
    The window for biotech IPOs remains wide open and six more companies have charged through it, raising more than $568 million in the span of 24 hours. The first was Eidos Therapeutics (NASDAQ: EIDX), which raised $106 million in its stock market debut. The San Francisco company priced its IPO late Tuesday, selling 6.25 million […]
  • What’s Hot in Seattle Biotech: Tech, Life Sciences Convergence & More June 19, 2018
    Like a good cup of coffee, Seattle’s life sciences ecosystem is a balanced blend of complementary parts: research to find the underpinnings of disease, and information technology that helps scientists make sense of the data. That convergence was on display last week at Xconomy’s annual What’s Hot in Seattle Biotech event. Here are a few […]
  • BioXcel Therapeutics Appoints Vincent O’Neill Chief Medical Officer June 19, 2018
    Vincent O’Neill has been appointed senior vice president and chief medical officer of BioXcel Therapeutics (NASDAQ: BTAI). O’Neill had been serving as chief medical officer of the Branford, CT, company on a consulting basis since last July. His experience also includes senior roles at Genentech, Sanofi (NYSE: SNY), GlaxoSmithKline (NYSE: GSK), and Mirna Therapeutics. Earlier […]
  • Former Walgreens Exec Leider Joins Gelesis as Chief Medical Officer June 19, 2018
    Gelesis has appointed Harry Leider to serve as the Boston company’s chief medical officer and executive vice president. Leider most recently worked at Walgreens Boots Alliance (NASDAQ: WBA), where he was chief medical officer and group vice president. His experience includes executive posts at Ameritox, XLHealth, and HealthNet. Since 2015, Leider has also been a […]
  • In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine June 19, 2018
    Roche this morning agreed to acquire the part of Foundation Medicine it didn’t already own, another big vote of confidence in tests that analyze a patient’s cancer genes and the drugs that can target them. Roche will pay $137 per share, or $2.4 billion, for the remaining stock of Foundation (NASDAQ: FMI), of Cambridge, MA. […]
  • Sarepta’s Data Are First in Rush for Duchenne Gene Therapy June 19, 2018
    It’s far too early to say whether gene therapy can treat Duchenne muscular dystrophy, a deadly genetic disease. But the first clinical data have arrived, with Sarepta Therapeutics today reporting encouraging preliminary results from three patients. Sarepta (NASDAQ: SRPT), of Cambridge, MA, is conducting an early-stage study of its experimental treatment known as AAVrh74.MHCK7.micro-Dystrophin. The […]
  • Emulate Adds $36M to Expand “Organ Chip” Drug Research Technology June 19, 2018
    Emulate, a Boston-based startup that has developed small laboratory chips intended to replace the animal tests used in pharmaceutical research, has raised $36 million in financing. The Series C round of funding was led by Founders Fund. Also participating in the financing were new investors ALS Investment Fund, SciFi VC, and Glass Wall Syndicate, as […]
  • Decibel Hauls in $55M to Bring Multiple Hearing Drugs to the Clinic June 19, 2018
    [Updated, 6/19/18, 4:20 p.m. See below.] Hearing loss affects millions of Americans, but so far, drug companies have not yet brought treatments to the market. Decibel Therapeutics aims to pioneer the discovery and development of therapies addressing multiple forms of hearing loss. The startup has quietly built a pipeline of experimental drugs, and as those […]
  • As Sarepta Preps Data, FDA Lifts Hold on Solid’s Duchenne Gene Therapy June 18, 2018
    The race to use gene therapy to treat Duchenne muscular dystrophy, a progressive, deadly genetic disease that affects boys, is heating up this week. The FDA just cleared Solid Biosciences to resume clinical testing of a Duchenne gene therapy, a day before Sarepta Therapeutics will report human clinical data from a rival treatment that also […]
  • Biotech Beware, Your Culture Is Showing June 15, 2018
    In a recent survey of 220 scientists, 60 percent of the respondents reported having experienced harassment at a conference at some point in their careers. Even more astounding is the fact that 82 percent of those who reported harassment did not report it when it occurred. That’s why it’s easy to say, “How big of […]
  • Teva’s Migraine Drug Fails in Phase 3 for Chronic Cluster Headaches June 15, 2018
    Teva Pharmaceutical’s bid to add a new therapeutic application for its experimental migraine-prevention drug has faltered in a late-stage study. Israel-based Teva (NYSE: TEVA) said Friday that it is stopping a Phase 3 clinical trial testing its drug, fremanezumab, for prevention of chronic cluster headaches. According to the company, an analysis found that the study […]
  • 30Ventures Seeks $15M to Fund Startups in Healthcare, Water Tech June 15, 2018
    30Ventures, one of the newest additions to Wisconsin’s venture capital scene, quietly revealed plans this week to raise up to $15 million for its debut fund, which will back healthcare and water and chemistry-related technologies in the Midwest. The Madison, WI-based firm disclosed fundraising details in a document filed with federal securities regulators on Thursday. […]
  • Metabolon CEO John Ryals Retires, Rohan Hastie Named Successor June 15, 2018
    John Ryals has retired from Metabolon, where he was president and CEO. Ryals, co-founder of the Research Triangle Park, NC, company, will remain on the board of directors. Rohan Hastie, Metabolon’s chief business officer, has been promoted to president and CEO. Metabolon has developed technology that analyzes processes related to metabolism. The company’s tests have […]
  • Northern Biologics’ Rahul Ballal Joins Imara as CEO June 15, 2018
    Rahul Ballal has been named CEO of Cambridge drug developer Imara. Ballal most recently served as chief business officer of Northern Biologics. Imara launched in 2016 backed by $31 million in financing to develop drugs for sickle cell disease and other blood disorders. The company’s lead sickle cell disease compound, IMR-687, is in mid-stage clinical […]
  • Bio Roundup: Not-BIO Party Foul, CRISPR Drama, Sickle Cell Updates June 15, 2018
    This week brought a sobering reminder of how far away we are from true gender equality in the life sciences. An industry party held during BIO’s annual meeting in Boston last week featured scantily clad women with company logos painted on their bodies—two years after the infamous party at the J.P. Morgan party in San […]
  • For Sickle Cell, a Complex Disease, New Drugs Could Bring Complex Costs June 15, 2018
    Cassandra Trimnell has sickle cell disease. She also loves to travel. For her 30th birthday last year, she and her husband planned a trip to Indonesia, and she figured she would be fine. Growing up in Iowa, she was sick all the time, in and out of hospitals with severe pain episodes, or “crises,” and […]
  • Bluebird’s Upgraded Gene Therapy Shows Promise For Sickle Cell Patients June 15, 2018
    Bluebird Bio has new clinical data this morning that, while early and only from a handful of patients, are the most significant evidence to date that gene therapy might help people with sickle cell disease, a genetic disorder without an effective treatment that afflicts millions around the world. The data, presented at the European Hematology […]

RSS in the pipeline

RSS The Street